Agios to receive $1.1B in milestone payments for vorasidenib approval (NASDAQ:AGIO)

study

Agios PharmaceuticalsNASDAQ: AGIWAmerican drugmaker ABM said it will receive $1.1 billion in milestone payments after the U.S. Food and Drug Administration approved its drug furasidinib to treat malignant brain tumors.

The biotech company said it will receive $905 million from Royalty Pharma in connection with its recent royalty agreement.According to the statement

1.1bAgiosApprovalmilestoneNASDAQAGIOPaymentsReceivevorasidenib